Cipher Pharmaceuticals Inc (TSE:CPH) – Analysts at Cormark reduced their Q1 2017 EPS estimates for Cipher Pharmaceuticals in a research note issued to investors on Monday. Cormark analyst D. Novak now anticipates that the firm will post earnings of $0.07 per share for the quarter, down from their prior forecast of $0.10. Cormark also issued estimates for Cipher Pharmaceuticals’ Q2 2017 earnings at $0.04 EPS, Q3 2017 earnings at $0.08 EPS and FY2017 earnings at $0.22 EPS.
Other equities analysts have also issued reports about the stock. TD Securities reiterated a “buy” rating and issued a C$7.50 target price on shares of Cipher Pharmaceuticals in a report on Thursday, August 11th. GMP Securities lowered shares of Cipher Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 11th.
Cipher Pharmaceuticals (TSE:CPH) traded up 0.60% during trading on Tuesday, reaching $5.05. 5,500 shares of the company’s stock traded hands. The company has a 50 day moving average price of $5.29 and a 200-day moving average price of $6.61. Cipher Pharmaceuticals has a 12-month low of $4.81 and a 12-month high of $8.18. The company’s market cap is $132.28 million.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.
Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.